Needham & Company LLC set a $25.00 target price on Amphastar Pharmaceuticals (NASDAQ:AMPH) in a research note released on Friday. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also issued reports on AMPH. Zacks Investment Research raised Amphastar Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, October 9th. BidaskClub lowered Amphastar Pharmaceuticals from a strong-buy rating to a buy rating in a research note on Thursday, October 4th. Wells Fargo & Co reissued a buy rating on shares of Amphastar Pharmaceuticals in a research note on Friday. Finally, ValuEngine raised Amphastar Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, August 17th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus price target of $23.00.

Shares of AMPH stock traded up $0.88 on Friday, reaching $21.59. 735,306 shares of the company’s stock were exchanged, compared to its average volume of 117,925. Amphastar Pharmaceuticals has a 52 week low of $14.40 and a 52 week high of $21.65. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.24 and a current ratio of 1.94. The firm has a market capitalization of $890.44 million, a P/E ratio of 56.82, a P/E/G ratio of 8.77 and a beta of 1.38.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The firm had revenue of $75.54 million during the quarter, compared to analyst estimates of $76.84 million. During the same period last year, the company earned $0.07 EPS. Amphastar Pharmaceuticals’s quarterly revenue was up 30.5% compared to the same quarter last year. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals will post 0.1 EPS for the current year.

In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 16,095 shares of Amphastar Pharmaceuticals stock in a transaction on Friday, November 9th. The stock was sold at an average price of $20.99, for a total transaction of $337,834.05. Following the completion of the sale, the general counsel now directly owns 204,805 shares of the company’s stock, valued at approximately $4,298,856.95. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard K. Prins sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $17.82, for a total value of $178,200.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,502 shares of company stock valued at $558,373. 31.50% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of AMPH. Principal Financial Group Inc. raised its position in Amphastar Pharmaceuticals by 2.2% during the 1st quarter. Principal Financial Group Inc. now owns 273,428 shares of the company’s stock valued at $5,127,000 after purchasing an additional 5,789 shares in the last quarter. Meeder Asset Management Inc. raised its position in Amphastar Pharmaceuticals by 259.8% during the 2nd quarter. Meeder Asset Management Inc. now owns 10,486 shares of the company’s stock valued at $160,000 after purchasing an additional 7,572 shares in the last quarter. Piedmont Investment Advisors LLC bought a new stake in Amphastar Pharmaceuticals during the 2nd quarter valued at $128,000. State of Wisconsin Investment Board raised its position in Amphastar Pharmaceuticals by 29.3% during the 2nd quarter. State of Wisconsin Investment Board now owns 36,200 shares of the company’s stock valued at $552,000 after purchasing an additional 8,200 shares in the last quarter. Finally, Sei Investments Co. raised its position in Amphastar Pharmaceuticals by 4.9% during the 2nd quarter. Sei Investments Co. now owns 67,934 shares of the company’s stock valued at $1,037,000 after purchasing an additional 3,193 shares in the last quarter. 42.86% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Recommended Story: How dollar cost averaging works

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.